Oxford BioDynamics (Oxford BioDynamics) Construction In Progress : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Construction In Progress?

Oxford BioDynamics Construction In Progress Historical Data

The historical data trend for Oxford BioDynamics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Construction In Progress Chart

Oxford BioDynamics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Construction In Progress

Get a 7-Day Free Trial

Oxford BioDynamics Semi-Annual Data
	Sep13	Sep14	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Construction In Progress	Get a 7-Day Free Trial														-	-	-	-	-

Oxford BioDynamics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Oxford BioDynamics (Oxford BioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

OBD:UK

Address

Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB

Website

https://www.oxfordbiodynamics.com

Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.